422 related articles for article (PubMed ID: 35479084)
21. MOICS, a novel classier deciphering immune heterogeneity and aid precise management of clear cell renal cell carcinoma at multiomics level.
Liu Y; Qi L; Ye B; Wang A; Lu J; Qu L; Luo P; Wang L; Jiang A
Cancer Biol Ther; 2024 Dec; 25(1):2345977. PubMed ID: 38659199
[TBL] [Abstract][Full Text] [Related]
22. Renal enhanced CT images reveal the tandem mechanism between tumor cells and immunocytes based on bulk/single-cell RNA sequencing.
Liang H; Wu K; Wu R; Huang K; Deng Z; Chen H
Funct Integr Genomics; 2023 Mar; 23(2):88. PubMed ID: 36933049
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive Evaluation of the m
Yu M; Liu X; Xu H; Shen S; Wang F; Chen D; Li G; Wang Z; Zuo Z; Zhao A
Front Immunol; 2022; 13():818120. PubMed ID: 35784363
[TBL] [Abstract][Full Text] [Related]
24. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
25. Multi-omics analysis uncovers clinical, immunological, and pharmacogenomic implications of cuproptosis in clear cell renal cell carcinoma.
Zhu M; Li Y; Wang Y; Lin P; Mi J; Zhong W
Eur J Med Res; 2023 Jul; 28(1):248. PubMed ID: 37481601
[TBL] [Abstract][Full Text] [Related]
26. Integrated multi-omics analyses reveal that BCAM is associated with epigenetic modification and tumor microenvironment subtypes of clear cell renal cell carcinoma.
Zhao J; Liang J; Yang Y; Sun G; Zhang X; Zhao J; Hu X; Chen J; Zhu S; Ni Y; Zhang Y; Dai J; Wang Z; Wang Z; Zeng Y; Yao J; Chen N; Shen P; Liu Z; Zeng H
Clin Epigenetics; 2022 Aug; 14(1):99. PubMed ID: 35941663
[TBL] [Abstract][Full Text] [Related]
27. Leveraging diverse cell-death patterns to predict the prognosis, immunotherapy and drug sensitivity of clear cell renal cell carcinoma.
Zhang X; Zhang M; Song L; Wang S; Wei X; Shao W; Song N
Sci Rep; 2023 Nov; 13(1):20266. PubMed ID: 37985807
[TBL] [Abstract][Full Text] [Related]
28. Decoding the Immune Microenvironment of Clear Cell Renal Cell Carcinoma by Single-Cell Profiling to Aid Immunotherapy.
Liu J; Xu J; Zhang T; Xu K; Bao P; Zhang Z; Xue K; He R; Ma L; Wang Y
Front Immunol; 2022; 13():791158. PubMed ID: 35812372
[TBL] [Abstract][Full Text] [Related]
29. Predicting prognosis, immunotherapy and distinguishing cold and hot tumors in clear cell renal cell carcinoma based on anoikis-related lncRNAs.
Hao C; Li R; Lu Z; He K; Shen J; Wang T; Qiu T
Front Immunol; 2023; 14():1145450. PubMed ID: 37359524
[TBL] [Abstract][Full Text] [Related]
30. Redox Metabolism-Associated Molecular Classification of Clear Cell Renal Cell Carcinoma.
Wei X; Deng W; Dong Z; Luo Y; Hu X; Zhang J; Xie Z; Zheng T; Tan Y; Tang Z; Li H; Na N
Oxid Med Cell Longev; 2022; 2022():5831247. PubMed ID: 35096270
[TBL] [Abstract][Full Text] [Related]
31. A genomic instability-derived risk index predicts clinical outcome and immunotherapy response for clear cell renal cell carcinoma.
Wu S; Li X
Bioengineered; 2021 Dec; 12(1):1642-1662. PubMed ID: 33955826
[TBL] [Abstract][Full Text] [Related]
32. Protein Arginine Methyltransferases Refine the Classification of Clear Cell Renal Cell Carcinoma with Distinct Prognosis and Tumor Microenvironment Characteristics.
Ye S; Tian X; Anwaier A; Wei S; Liu W; Su J; Zhu S; Dai B; Gu J; Qu Y; Xu W; Zhang H; Ye D
Int J Biol Sci; 2023; 19(14):4552-4570. PubMed ID: 37781030
[No Abstract] [Full Text] [Related]
33. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
34. Large-scale transcriptome profiles reveal robust 20-signatures metabolic prediction models and novel role of G6PC in clear cell renal cell carcinoma.
Xu WH; Xu Y; Tian X; Anwaier A; Liu WR; Wang J; Zhu WK; Cao DL; Wang HK; Shi GH; Qu YY; Zhang HL; Ye DW
J Cell Mol Med; 2020 Aug; 24(16):9012-9027. PubMed ID: 32567187
[TBL] [Abstract][Full Text] [Related]
35. The multi-omics analyses of acsl1 reveal its translational significance as a tumor microenvironmental and prognostic biomarker in clear cell renal cell carcinoma.
Yang Y; Liang J; Zhao J; Wang X; Feng D; Xu H; Shen Y; Zhang Y; Dai J; Wang Z; Wei Q; Liu Z
Diagn Pathol; 2023 Aug; 18(1):96. PubMed ID: 37608295
[TBL] [Abstract][Full Text] [Related]
36. Pyroptosis-Related Subtypes Predict the Response of Clear Cell Renal Cell Carcinoma to Targeted Therapy.
Ma J; Kang Z; Yang G; Wang X; Si M; Wang Y; Li G; Bai S; Zeng F; Li M; Wang Z; Wang L; Xu W
Front Biosci (Landmark Ed); 2023 Dec; 28(12):334. PubMed ID: 38179741
[TBL] [Abstract][Full Text] [Related]
37. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
38. Characterization of Hypoxia-Related Molecular Subtypes in Clear Cell Renal Cell Carcinoma to Aid Immunotherapy and Targeted Therapy
Zhong W; Zhong H; Zhang F; Huang C; Lin Y; Huang J
Front Mol Biosci; 2021; 8():684050. PubMed ID: 34250018
[No Abstract] [Full Text] [Related]
39. Neutrophil extracellular traps-associated modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of clear cell renal cell carcinoma.
Teng ZH; Li WC; Li ZC; Wang YX; Han ZW; Zhang YP
Front Oncol; 2022; 12():1094248. PubMed ID: 36620592
[TBL] [Abstract][Full Text] [Related]
40. Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinoma.
Xu Z; Jiang W; Liu L; Qiu Y; Wang J; Dai S; Guo J; Xu J
Cancer Immunol Immunother; 2024 Apr; 73(5):95. PubMed ID: 38607586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
